ScholarIQanswers from OpenAlex & ORCID
Kirsten van Nimwegen
ResearcherPublications, citations & collaboration network
Kirsten van Nimwegen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Kirsten van Nimwegen have?
ScholarIQindexed works
Kirsten van Nimwegen has 7 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kirsten van Nimwegen have?
ScholarIQcitation count
Kirsten van Nimwegen has 82 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Kirsten van Nimwegen?
ScholarIQh-index
Kirsten van Nimwegen has an h-index of 2 in OpenAlex.
What is the i10-index of Kirsten van Nimwegen?
ScholarIQi10-index
Kirsten van Nimwegen has an i10-index of 1 in OpenAlex.
What is the OpenAlex record for Kirsten van Nimwegen?
ScholarIQopenalex
The OpenAlex for Kirsten van Nimwegen is on the source record.
What are the most-cited papers on Kirsten van Nimwegen?
ScholarIQmost cited works
Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment
Lieneke F.M. Ariëns, Kirsten van Nimwegen, M Shams, David De Bruin, Jorien van der Schaft, Harmieke van Os‐Medendorp, Marjolein de Bruin‐Weller
P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK
Ivan Špıčka, Ido Lapidot, Maximilian Merz, Jakub Radocha, Martin Štork, Tomáš Jelı́nek, Alexandra Jungová, Jiří Minařík, J. Soukup, Michel van Speybroeck, Nolen Joy Perualila, Joris Diels, João Duarte Mendes, Kirsten van Nimwegen, Kai Strobel, S Wischlen, Henrik Sliwka, Blanca Gros Otero, Roman Hájek
P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
Philippe Moreau, Niels W.C.J. van de Donk, Michel Delforge, Hermann Einsele, Valerio De Stefano, Aurore Perrot, Britta Besemer, Charlotte Pawlyn, Lionel Karlin, Salomon Manier, Xavier Leleu, Pushpike Thilakarathne, Joris Diels, Katharine S. Gries, Nichola Erler-Yates, Kirsten van Nimwegen, Raúl Balsera Moraño, Vadim Strulev, Imène Haddad, Rachel Kobos, Jennifer Smit, Alexander Mclean Marshall, Mary Slavcev, María‐Victoria Mateos, Katja Weisel
P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison
Michel Delforge, Sébastien Anguille, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Van de Broek, Joris Diels, Nichola Erler-Yates, Sébastien Van Causenbroeck, Kirsten van Nimwegen, Sophie Vandervennet, Susanne Lub, Marie-Christiane Madeleine Vekemans
Inpatient vs outpatient treatment management with teclistamab in relapsed and refractory multiple myeloma: A cost and healthcare resource utilization analysis
Niels W.C.J. van de Donk, Ruth Wester, Inger S. Nijhof, Claire Albrecht, Raúl Balsera Moraño, Cristina Entrala, Kirsten van Nimwegen